Cursus Bio is a leading biotech company pioneering innovation in the treatment of obesity and metabolic diseases. We are developing next-generation gene-based obesity therapeutics that overcomes the limitations of existing GLP-1 analogs. By targeting adipocytes directly with a 'First-in-Class' mechanism, we are setting a new therapeutic paradigm. Our core asset, the MicroLock™ patch technology, is a proprietary transdermal drug delivery platform that enables the quantitative delivery of high-dose drugs. It has been validated to achieve efficacy comparable or superior to that of injectables, significantly improving patient access to obesity and metabolic disease treatments through a patient-friendly administration method. Furthermore, we have established a sustainable revenue model through our OEM/ODM business for microneedle cosmetics and pharmaceuticals, leveraging our CGMP-certified manufacturing facilities.

MicroArray Patch, Cosmetic and Medical Microneedle, Obesity Treatment, Gene Therapy